Treatment of Hyperhidrosis With Oxybutynin

Schöllhammer, M.; Miséry, Laurent

doi:10.1001/archderm.143.4.544

Cited by 19 publications

(12 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug exerts anticholinergic effects via the muscarinic M3 receptor. Because the same receptor is expressed in the salivary glands, the most common side effect is dry mouth (3,9,16,18-20,25,26). …”

Section: Discussionmentioning

confidence: 99%

“…The idea of using an oral anticholinergic for the treatment of hyperhidrosis is not original, as it was first reported in 1951 (17). There are several clinical reports and case series on the use of oxybutynin to treat plantar sweating, but to the best of our knowledge, there have been no randomized clinical trials on the subject so far (16,18-20,26,29-32). …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy

Costa¹,

Leão²,

Succi³

et al. 2014

Clinics

View full text Add to dashboard Cite

OBJECTIVE:Hyperhidrosis is a common disease, and thoracoscopic sympathectomy improves its symptoms in up to 95% of cases. Unfortunately, after surgery, plantar hyperhidrosis may remain in 50% of patients, and compensatory sweating may be observed in 70%. This clinical scenario remains a challenge. Our objective was to evaluate the effectiveness of oxybutynin in the treatment of persistent plantar hyperhidrosis and compensatory sweating and its effects on quality of life in women after thoracoscopic sympathectomy.METHOD:We conducted a prospective, randomized study to compare the effects of oxybutynin at 10 mg daily and placebo in women with persistent plantar hyperhidrosis. The assessment was performed using a quality-of-life questionnaire for hyperhidrosis and sweating measurement with a device for quantifying transepidermal water loss. Clinicaltrials.gov: NCT01328015.RESULTS:Sixteen patients were included in each group (placebo and oxybutynin). There were no significant differences between the groups prior to treatment. After oxybutynin treatment, there was a decrease in symptoms and clinical improvement based on the quality-of-life questionnaire (before treatment, 40.4 vs. after treatment, 17.5; p = 0.001). The placebo group showed modest improvement (p = 0.09). The outcomes of the transepidermal water loss measurements in the placebo group showed no differences (p = 0.95), whereas the oxybutynin group revealed a significant decrease (p = 0.001). The most common side effect was dry mouth (100% in the oxybutynin group vs. 43.8% in the placebo group; p = 0.001).CONCLUSION:Oxybutynin was effective in the treatment of persistent plantar hyperhidrosis, resulting in a better quality of life in women who had undergone thoracoscopic sympathectomy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Randomized trial - oxybutynin for treatment of persistent plantar hyperhidrosis in women after sympathectomy

Costa¹,

Leão²,

Succi³

et al. 2014

Clinics

View full text Add to dashboard Cite

show abstract

“…Its use for treating hyperhidrosis has only been described in three case reports on patients with hyperhidrosis and one series of 14 patients with compensatory hyperhidrosis. [12][13][14][15] Daily practice has shown us that oxybutynin at low doses (up to 10 mg/day) seems to generate fewer side effects, while it is still effective to reduce sudoresis in patients with facial hyperhidrosis.…”

Section: Introductionmentioning

confidence: 99%

The use of oxybutynin for treating facial hyperhidrosis

Wolosker

Campos

Kauffman

et al. 2011

An. Bras. Dermatol.

View full text Add to dashboard Cite

BACKGROUND: Facial hyperhidrosis is a disease that may lead patients to serious emotional disturbances. Video-assisted thoracic sympathectomy provides excellent resolution of facial hyperhidrosis, but is associated with certain complications. The most frequent and important complication is compensatory hyperhidrosis. Especially in patients who have undergone resection of the second thoracic ganglion, the risk of severe compensatory hyperhidrosis is higher, which may cause dissatisfaction with the procedure. OBJECTIVE: The aim of this study was to evaluate the efficacy of the use of low doses of oxybutynin in treating facial hyperhidrosis as well as the level of patient satisfaction with its use. METHODS: 25 patients with facial hyperhidrosis were treated with oxybutynin. The patients underwent 2 evaluations: before and after treatment. These evaluations were used to assess the patients' clinical improvement and quality of life. RESULTS: We observed that more than 75% of the patients evolved with an improvement in facial hyperhidrosis, and 52% of them presented a great improvement. CONCLUSION: Treatment of facial hyperhidrosis with oxybutynin is a good alternative to sympathectomy, since it presents good results and improves quality of life, in addition to not exposing patients to the risk of experiencing the side effects of sympathectomy. Keywords: Advanced treatment; Clinical protocols; Hyperhidrosis; Indicators of quality of life; Sympathectomy; Sweating Resumo: FUNDAMENTOS: Hiperidrose facial é uma doença que pode levar os pacientes a sérios distúrbios emocionais. A simpatectomia torácica vídeo-assistida proporciona excelente resolução da hiperidrose facial, mas está associada a algumas complicações, sendo a mais freqüente e mais importante a hiperidrose compensatória. Especialmente em pacientes submetidos à ressecção do segundo gânglio torácico, o risco de hiperidrose compensatória grave é maior, o que pode causar insatisfação com o procedimento. OBJETIVO: O objetivo deste estudo foi avaliar a eficácia e a satisfação dos pacientes com o uso da oxibutinina em doses baixas para tratar a hiperidrose facial em uma série grande de pacientes. MÉTODOS: 25 pacientes com hiperidrose facial foram tratados com oxibutinina. Os pacientes foram submetidos a duas avaliações: antes e depois do tratamento. Estas foram usadas para avaliar a melhoria clínica e a qualidade de vida. RESULTADOS: Observou-se que mais de 75% dos pacientes evoluíram com melhora na hiperidrose facial, sendo que 52% deles apresentaram uma grande melhora. CONCLUSÃO: O tratamento da hiperidrose facial com oxibutinina é uma boa alternativa à simpatectomia, visto que apresenta bons resultados e melhora a qualidade de vida, e os pacientes não correm o risco dos efeitos colaterais da simpatectomia.

show abstract

“…One effect observed in these patients has been diminished sudoresis. Its use for treating hyperhidrosis has only been described in three case reports [10][11][12], including one series of 14 patients with compensatory hyperhidrosis after VATS [13] and another series of 21 patients with postmenopausal hyperhidrosis [14].…”

Section: Introductionmentioning

confidence: 99%